Matches in Wikidata for { <http://www.wikidata.org/entity/Q100693289> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q100693289 description "2020 ވަނަ އަހަރުގެ އޮކްޓޯބަރުމަހުގެ 16ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ލިޔުމެއް" @default.
- Q100693289 description "artículu científicu espublizáu n'ochobre de 2020" @default.
- Q100693289 description "scientific article published on 16 October 2020" @default.
- Q100693289 description "wetenschappelijk artikel" @default.
- Q100693289 description "наукова стаття, опублікована 16 жовтня 2020" @default.
- Q100693289 name "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 name "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 name "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 type Item @default.
- Q100693289 label "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 label "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 label "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 prefLabel "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 prefLabel "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 prefLabel "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 P1433 Q100693289-56182D91-02E0-4D98-AC5B-A1433EC0379B @default.
- Q100693289 P1476 Q100693289-0C84BCBE-47AE-4644-9733-35C9A9AA770E @default.
- Q100693289 P2093 Q100693289-1AC00AAD-2E30-45A6-865F-0F1C54AC36CD @default.
- Q100693289 P2093 Q100693289-614D692D-E54E-4583-AF13-DE5DA5B48530 @default.
- Q100693289 P2093 Q100693289-82675B40-476F-45B9-BF20-FC4B425E1596 @default.
- Q100693289 P2093 Q100693289-C23BA137-6A2D-4479-BF86-6A884430DF98 @default.
- Q100693289 P2093 Q100693289-DDDFADA6-3011-4C59-93EF-23421E83F91B @default.
- Q100693289 P275 Q100693289-b2822329-c0c1-40e5-bfb5-cef0f082c174 @default.
- Q100693289 P304 Q100693289-68A3A20A-BE97-435B-9FC8-A22C609E0603 @default.
- Q100693289 P31 Q100693289-89F7E98B-FCD7-4C1B-A20A-B4FE55DECF5E @default.
- Q100693289 P356 Q100693289-A7923146-4628-4785-9EFD-9B0A3B00C8C4 @default.
- Q100693289 P433 Q100693289-4114B383-1773-4B65-B575-CA7CA51D3646 @default.
- Q100693289 P478 Q100693289-D5ED6C2A-F4F0-468C-8934-78935ACFDEAC @default.
- Q100693289 P50 Q100693289-0D660067-3582-45E7-8EB8-D115F7AE6734 @default.
- Q100693289 P50 Q100693289-0DC19987-E734-44E6-AEA1-CEC89A4B2CCD @default.
- Q100693289 P577 Q100693289-C75C3824-ED37-437F-B24D-140C1DDE6DD9 @default.
- Q100693289 P6216 Q100693289-719f3caf-3c8c-40ee-805a-3ff3fcd2707d @default.
- Q100693289 P698 Q100693289-E0F5AEF4-F86D-4E38-AF0B-4448DAE54F04 @default.
- Q100693289 P921 Q100693289-7F4B578B-8EA8-46E2-9D0C-FFE272A8D6ED @default.
- Q100693289 P356 BMJOPEN-2020-039639 @default.
- Q100693289 P698 33067297 @default.
- Q100693289 P1433 Q17003470 @default.
- Q100693289 P1476 "Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma" @default.
- Q100693289 P2093 "Gundram Jung" @default.
- Q100693289 P2093 "Helmut R Salih" @default.
- Q100693289 P2093 "Joseph Kauer" @default.
- Q100693289 P2093 "Martin Pflügler" @default.
- Q100693289 P2093 "Richard F Schlenk" @default.
- Q100693289 P275 Q34179348 @default.
- Q100693289 P304 "e039639" @default.
- Q100693289 P31 Q13442814 @default.
- Q100693289 P356 "10.1136/BMJOPEN-2020-039639" @default.
- Q100693289 P433 "10" @default.
- Q100693289 P478 "10" @default.
- Q100693289 P50 Q90365549 @default.
- Q100693289 P50 Q92021408 @default.
- Q100693289 P577 "2020-10-16T00:00:00Z" @default.
- Q100693289 P6216 Q50423863 @default.
- Q100693289 P698 "33067297" @default.
- Q100693289 P921 Q18553829 @default.